Bioinformatics products. Bioinformatics services. R&D.

GeneSpect Reporter for Somatic Cancer

Transforming genetic data into actionable insights for cancer patients

solution

Robust genetic data analysis 
from raw input to clinical insights

Accurate identification and interpretation of genetic alteration from tumor samples remains one of the biggest challenges in the clinical research world. By integrating information from renowned databases with our proprietary variant classification algorithm, we automate the whole process of data analysis, delivering insights faster and more comprehensively.

Raw genetic data

Raw genetic data

(NGS panel/WES/WGS)

Upload FASTQ or VCF files to launch analysis that can be performed for either paired (normal-tumor) samples or single tumor sample.

iFlowTM Engine

iFlowTM Engine

Secondary analysis

  • FastQ Quality Control
  • Alignment & BAM QC
  • Somatic Variant Calling (SNV, InDels, SV, CNV)
  • Variant Filtering and Annotation
GeneSpect Somatic Reporter

GeneSpect Somatic Reporter

Tertiary analysis

  • AMP/ACMG Variant Classification
  • FDA Recommendation Matching
    Genomic Databases Verification 
(cBioPortal, ClinVar, COSMIC)
  • Clinical Trials Searching

Product details

Advanced pipeline 
for secondary analysis

Advanced pipeline 
for secondary analysis

Advanced pipeline 
for secondary analysis

We employ advanced bioinformatic tools for secondary analysis, which enables us to extract variants that warrant further investigation. Tailored to the specific tumor type, our algorithms excel in distinguishing subclonal variants from potential false-positive calls.
In the context of blood cancer, our precision extends to detecting variants with a Variant Allele Frequency (VAF) below 0.5%, capturing the genetic profile of all single cancer cells represented by tumor sample.

Proprietary variant AMP classification algorithm

Proprietary variant AMP classification algorithm

Proprietary variant AMP classification algorithm

The Reporter boasts proprietary algorithms for 
AMP classification, ensuring accurate categorization 
of genetic variants. Drawing information from a broad spectrum of genomic and clinical databases, it provides the most accurate predictions of variant actionability and clinical significance, highlighting the most promising therapeutic targets.

Data-driven conclusions

Data-driven conclusions

Data-driven conclusions

We rely on the expertise of well-established genetic databases such as CIViC, cBioPortal, COSMIC, and Cancer Hotspots for the interpretation of somatic variants. By integrating data from these reputable sources, we ensure a deep and comprehensive analysis of the correlations between specific genetic variants and a particular cancer type. This approach allows us 
to deliver more insightful and clinically relevant findings in our research endeavors.

Therapy recommendations matching with tumor genetic makeup

Therapy recommendations matching with tumor genetic makeup

Therapy recommendations matching with tumor genetic makeup

Our approach involves delivering precise therapy recommendations, aligning with FDA-approved treatments, while taking into account the patient’s tumor type and specific genetic alterations. This approach empowers us to offer both on-label and off-label treatments, which, in certain instances, may prove advantageous, particularly when considering emergency access to drug technologies (RTDL).

Precise clinical trials search

Precise clinical trials search

Precise clinical trials search

Precise clinical trial searches are crucial in modern healthcare and research – especially for those patients, who may consider participation in clinical trials as their only treatment option. We specifically search for clinical trials that incorporate patient’s tumor type and specific genetic lesions as eligibility criteria. This approach ensures that patients with unique genetic profiles receive information about the most accurate clinical trials being in the recruitment phase.

Easy-to-interpret report 
that collects insights based 
on all significant findings

Easy-to-interpret report 
that collects insights based 
on all significant findings

Our end-to-end solution culminates with a comprehensive report, that 
encapsulates every clinically relevant discovery. The report meticulously 
delineates TIER I and TIER II variants, ensuring that only the most critical findings are emphasized. Moreover, we furnish FDA therapy matches, aligning treatment options with regulatory approvals.
In addition, the report showcases the twenty latest open clinical trials, ensuring patients have access to cutting-edge opportunities. Furthermore, it provides variant frequency data from somatic databases, enriching our understanding of the tumor genetic landscape and its implications.
Our reports are fully customizable, allowing them to be tailored to the specific criteria of research laboratories and research objectives. This flexibility ensures that each report serves as a precise and adaptable tool for diverse scientific inquiries.

Easy-to-interpret report 
that collects insights based 
on all significant findings

Resources

Whitepapers and tech notes

Whitepapers and tech notes

Blog posts and case studies

Blog posts and case studies

Flyers

Flyers

Webinars

Webinars

<h2>Want to know more?</h2>

Want to know more?

Get in touch with us.